There isn't any guarantee that the company will be a good investment on the force or direction of those trends alone. But ...

Clinical trials of single-agent targeted drugs have shown limited efficacy. In the only trial of single-agent immunotherapy ...

A risk stratification algorithm may be able to predict which patients with advanced chronic liver disease are at risk of ...

Fintel reports that on October 25, 2024, Citigroup downgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Buy to ...

Global Trust Asset Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 20.0% in the third ...

Equities researchers at Leerink Partnrs decreased their Q3 2024 EPS estimates for Bristol-Myers Squibb in a research report ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight ...

Foundation has awarded Baylor College of Medicine Global Health $2.25 million (about K3.9 billion) for a three-year ...

A newly described stage of a lymph node-like structure seen in liver tumors after presurgical immunotherapy may be vital to ...

Any long-term dividend investors should consider buying and holding the ETF forever. Here is what makes this ETF so good. 1.

The long-standing debate as to when to start anticoagulation in patients with an acute ischemic stroke and atrial ...